Latest Drug Manufacturing News

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Clever Culture Systems has validated and launched an AI-driven analysis module for smaller contact plates, significantly expanding its pharmaceutical market reach and recurring revenue potential.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.